Literature DB >> 25218680

Brain atrophy in peritoneal dialysis and CKD stages 3-5: a cross-sectional and longitudinal study.

Kazuhiko Tsuruya1, Hisako Yoshida2, Yusuke Kuroki3, Masaharu Nagata4, Tohru Mizumasa5, Koji Mitsuiki3, Takashi Yoshiura6, Makoto Hirakawa7, Hidetoshi Kanai8, Kei Hori9, Hideki Hirakata3, Takanari Kitazono4.   

Abstract

BACKGROUND: Brain atrophy has been reported in patients with end-stage renal disease receiving hemodialysis, although its mechanism is unknown. However, little is known regarding brain atrophy in patients receiving peritoneal dialysis (PD). Therefore, we examined brain volume and its annual change over 2 years in PD patients compared with patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). STUDY
DESIGN: Cross-sectional and longitudinal cohort. SETTING & PARTICIPANTS: 62 PD patients and 69 patients with NDD-CKD with no history of cerebrovascular disease who underwent brain magnetic resonance imaging (MRI) were recruited in a cross-sectional study. Among them, 34 PD patients and 61 patients with NDD-CKD, who underwent a second brain MRI after 2 years, were recruited in a longitudinal study. PREDICTOR: PD therapy versus NDD-CKD. OUTCOMES & MEASUREMENTS: T1-weighted magnetic resonance images were analyzed. Total gray matter volume (GMV), total white matter volume (WMV), and cerebrospinal fluid space volume were segmented, and each volume was quantified using statistical parametric mapping software. Normalized GMV and WMV values were calculated by division of GMV and WMV by intracranial volume to adjust for variations in head size. We compared normalized GMV and normalized WMV between PD patients and patients with NDD-CKD in the cross-sectional study and the annual change in normalized GMV in the longitudinal study.
RESULTS: In the cross-sectional study, normalized GMV, which was correlated inversely with age, was lower in PD patients than in patients with NDD-CKD. However, normalized WMV, which was not correlated with age, was comparable between the groups. Annual change in normalized GMV was significantly higher in PD patients than in patients with NDD-CKD. These differences remained significant even after adjustment for potential confounding factors. LIMITATIONS: A short observation period and high dropout rate in the longitudinal study.
CONCLUSIONS: Decline in normalized GMV is faster in PD patients than in patients with NDD-CKD.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease (CKD); brain atrophy; brain volume; gray matter volume (GMV); magnetic resonance imaging (MRI); peritoneal dialysis (PD); white matter volume (WMV)

Mesh:

Year:  2014        PMID: 25218680     DOI: 10.1053/j.ajkd.2014.07.011

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

Review 1.  Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages.

Authors:  Taimur Dad; Daniel E Weiner
Journal:  Semin Nephrol       Date:  2015-07       Impact factor: 5.299

2.  Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study.

Authors:  Prashanthi Vemuri; David S Knopman; Clifford R Jack; Emily S Lundt; Stephen D Weigand; Samantha M Zuk; Kaely B Thostenson; Robert I Reid; Kejal Kantarci; Yelena Slinin; Kamakshi Lakshminarayan; Cynthia S Davey; Anne Murray
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Associations of Early Kidney Disease With Brain Magnetic Resonance Imaging and Cognitive Function in African Americans With Type 2 Diabetes Mellitus.

Authors:  Barry I Freedman; Kaycee M Sink; Christina E Hugenschmidt; Timothy M Hughes; Jeff D Williamson; Christopher T Whitlow; Nicholette D Palmer; Michael E Miller; Laura C Lovato; Jianzhao Xu; S Carrie Smith; Lenore J Launer; Joshua I Barzilay; Robert M Cohen; Mark D Sullivan; R Nick Bryan; Benjamin C Wagner; Donald W Bowden; Joseph A Maldjian; Jasmin Divers
Journal:  Am J Kidney Dis       Date:  2017-06-23       Impact factor: 8.860

4.  Association between the Estimated Glomerular Filtration Rate and Brain Atrophy in Older Adults.

Authors:  Michael Grasing; Palash Sharma; Rebecca J Lepping; Robyn Honea; Jeffrey M Burns; William M Brooks; Aditi Gupta
Journal:  Am J Nephrol       Date:  2022-02-07       Impact factor: 4.605

5.  Co-Administration of Melatonin Effectively Enhances the Therapeutic Effects of Pioglitazone on Mesenchymal Stem Cells Undergoing Indoxyl Sulfate-Induced Senescence through Modulation of Cellular Prion Protein Expression.

Authors:  Yong Seok Han; Sang Min Kim; Jun Hee Lee; Sang Hun Lee
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

6.  Intradialytic hypotension and relationship with cognitive function and brain morphometry.

Authors:  Santiago Cedeño; Manuel Desco; Yasser Aleman; Nicolás Macías; Alberto Fernández-Pena; Almudena Vega; Soraya Abad; Juan Manuel López-Gómez
Journal:  Clin Kidney J       Date:  2020-12-05

Review 7.  Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?

Authors:  Boris Bikbov; Maria José Soler; Vesna Pešić; Giovambattista Capasso; Robert Unwin; Matthias Endres; Giuseppe Remuzzi; Norberto Perico; Ron Gansevoort; Francesco Mattace-Raso; Annette Bruchfeld; Andreja Figurek; Gaye Hafez
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

8.  Structural brain abnormalities in children and young adults with severe chronic kidney disease.

Authors:  Sophie Lijdsman; Marsh Königs; Marit S van Sandwijk; Antonia H Bouts; Koen van Hoeck; Huib de Jong; Marc Engelen; Jaap Oosterlaan; Frederike J Bemelman; Kim J Oostrom; Jaap W Groothoff
Journal:  Pediatr Nephrol       Date:  2021-11-20       Impact factor: 3.651

Review 9.  Covert vascular brain injury in chronic kidney disease.

Authors:  Kaori Miwa; Kazunori Toyoda
Journal:  Front Neurol       Date:  2022-07-25       Impact factor: 4.086

10.  Clinical Significance of Fronto-Temporal Gray Matter Atrophy in Executive Dysfunction in Patients with Chronic Kidney Disease: The VCOHP Study.

Authors:  Kazuhiko Tsuruya; Hisako Yoshida; Naoki Haruyama; Kiichiro Fujisaki; Hideki Hirakata; Takanari Kitazono
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.